Omicron Variant Dominance and Anti-Sars-cov-2 Vaccination Are Key Determinants for a Milder Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases. Charalampos Papagoras , Nikoleta Zioga , Vasileios Papadopoulos , Nafsika Gerolymatou , Eleni Kalavri , Christos Bounos , Theodora Simopoulou , George E. Fragoulis , Stylianos Panopoulos , Kalliopi Fragiadaki , Gerasimos Evangelatos , Vasiliki-Kalliopi Bournia , Aikaterini Arida , Anastasios Karamanakos , Maria Pappa , Evrydiki Kravvariti , Kleopatra Deftereou , Nikolaos Kougkas , Evangelia Zampeli , Evangelia Kataxaki , Konstantinos Melissaropoulos , Georgia Barouta , Alexandros Panagiotopoulos , Christos Koutsianas , Stamatis-Nick Liossis , Panagiotis Georgiou , Theodoros Dimitroulas , Maria G. Tektonidou , Dimitrios P. Bogdanos , Antonia Elezoglou , Paraskevi V. Voulgari , Petros P. Sfikakis , Dimitrios Vassilopoulos CLINICAL RHEUMATOLOGY（2023）
Key words
Anti-SARS-CoV-2 vaccine, Autoimmune rheumatic disease, COVID-19, Mortality, Omicron variant
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
